Rankings
▼
Calendar
VRTX
Vertex Pharmaceuticals Incorporated
$129B
Q2 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3.0B
+12.1% YoY
Gross Profit
$2.6B
86.3% margin
Operating Income
$1.2B
38.8% margin
Net Income
$1.0B
34.8% margin
EPS (Diluted)
$3.99
QoQ Revenue Growth
+7.0%
Cash Flow
Operating Cash Flow
$1.1B
Free Cash Flow
$927M
Stock-Based Comp.
$167M
Balance Sheet
Total Assets
$24.0B
Total Liabilities
$6.9B
Stockholders' Equity
$17.2B
Cash & Equivalents
$5.0B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.0B
$2.6B
+12.1%
Gross Profit
$2.6B
$2.3B
+12.5%
Operating Income
$1.2B
-$3.5B
+132.8%
Net Income
$1.0B
-$3.6B
+128.7%
Revenue Segments
TRIKAFTA/KAFTRIO
$2.6B
87%
Manufactured Product, Other
$236M
8%
ALYFTREK
$157M
5%
Geographic Segments
UNITED STATES
$1.8B
62%
Europe
$911M
31%
Other, Non U.S.
$206M
7%
← FY 2025
All Quarters
Q3 2025 →
VRTX Q2 2025 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena